The Personalized Immunotherapy Research Lab (PIRL) is a multi-investigator research group at the University of North Carolina’s School of Medicine, whose members bring together expertise in immunology, genomics, oncology, and machine learning. We work on developing cancer immunotherapies that use a patient’s immune system to attack specific mutations from their cancer.
The goal of our research is to use experimental insights and novel computational tools to start new investigator-initiated early phase clinical trials at UNC, the first of which is PANDA-VAC. We are also committed to open science through building open source research software, making experimental data unconditionally available, and disseminating results quickly through blog posts and preprints.
Recent Blog Posts
Over the past year and a half, PIRL has been working on several different therapeutic ideas for NUT carcinoma which I’ll describe in future blog posts. For now, I wanted to take stock of the current landscape of options for patients with incomplete surgical resections and make sense of when existing therapies do in fact work for a small number of patients.